Ottawa, October 26, 2023 – Health Canada has authorized Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of hemophilia B. Hemgenix is indicated for the...
Montreal, August 10, 2023 – Gene therapies for hemophilia A and B continue to move closer to becoming reality. Health Canada is currently evaluating two...
Kilimanjaro, the roof of Africa, a dormant volcano of 5,895 meters in height is a major hiking and climbing destination that about 35,000 people attempt...
The Canadian bleeding disorder treatment centres participed in a rigorous self-assessment of their services from November 2022 to February 2023. IT IS NOW TIME TO...
The 1st gene therapy for hemophilia B (factor IX deficiency) is currently undergoing an evaluation by Canadian health authorities. This review will determine whether or...